Palonosetron (PALO) versus granisetron (GRAN), both combined with dexamethasone (DEX) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin- or anthracycline plus cyclophosphamide-based regimens: Results of a phase III trial in Japanese patients

Sekine, Ikuo; Saito, Masaru; Aogi, K.; Yoshizawa, Hirohisa; Yanagita, Yasuhiro; Sakai, Hideki; Inoue, Kentaro; Kitagawa, Chiyoe; Ogura, Takuya; Mitsuhashi, Shoichi

doi:10.1200/jco.2008.26.15_suppl.20749

Search citation statements

Order By: Relevance

Paper Sections

Select...

Results1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2011

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty two studies were selected and retrieved for fulltext analysis. Of these studies, 27 were excluded for various reasons, described on Table 1 [16,[29][30][31][32][33][34][35][36][37][38][39][40][41][42][43].…”

Section: Resultsmentioning

confidence: 99%

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

Engel¹,

Clark²,

Clark³

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

Engel¹,

Clark²,

Clark³

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Update and new trends in antiemetic therapy: the continuing need for novel therapies

2011

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) continues to be one of the most feared side effects of chemotherapy. Inadequately controlled CINV can have a significant negative impact on quality of life and can in some cases compromise adherence to treatment. However, the repercussions of CINV for patients are often underestimated. Advances in our understanding of the physiology of CINV and the identification of risk factors have greatly contributed towards improvements in the control of CINV. A number of antiemetic agents are currently available for the prophylaxis and treatment of CINV, including 5-hydroxytryptamine 3 receptor antagonists corticosteroids, neurokinin 1 receptor antagonists, dopamine receptor antagonists, benzodiazepines, neuroleptics and cannabinoids. With the correct use of these agents, CINV can be prevented to a great extent; however, adherence to guidelines is disappointingly low. Furthermore, a significant number of patients still experience nausea and vomiting despite optimal treatment. More effective therapies are, therefore, greatly needed, with the ultimate goal of attaining complete control of CINV. This review focuses on the current understanding of CINV, problems associated with its management and the status of promising antiemetic therapies.

show abstract

Palonosetron (PALO) versus granisetron (GRAN), both combined with dexamethasone (DEX) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin- or anthracycline plus cyclophosphamide-based regimens: Results of a phase III trial in Japanese patients

Cited by 2 publications

References 0 publications

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

Update and new trends in antiemetic therapy: the continuing need for novel therapies

Contact Info

Product

Resources

About